BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...IL-2 therapy produces responses in Phase I/IIAlkermes plc (NASDAQ:ALKS) is expanding a melanoma cohort receiving ALKS 4230...
...multiple tumor types including heavily pretreated platinum-resistant ovarian cancer, triple-negative breast cancer and esophageal cancer. ALKS 4230...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...in vivo.Companies in bold have clinical cytokine products.ALKS 4230...
BioCentury | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

...to maximize the commercial infrastructure it has built in neuropsychiatry. Outside of neuroscience, Alkermes has ALKS 4230...
BioCentury | Oct 23, 2019
Company News

With MS approval looming, Alkermes restructures to seek sustainable profits

..."Alkermes Planning NDA for Combo" ). Deeper in its pipeline, Alkermes is prioritizing immuno-oncology asset ALKS 4230...
...μ opioid receptor Paul Bonanos, Associate Editor Vumerity, diroximel fumarate (ALKS 8700, BIIB098) samidorphan/olanzapine (ALKS 3831) ALKS 4230, rdb 1419, rdb 1450 Alkermes...
BioCentury | Nov 1, 2018
Company News

FDA panel snubs Alkermes’ antidepressant

...Behind it, Alkermes’ pipeline has ALKS 3831 in Phase III testing to treat schizophrenia, and ALKS 4230...
...Phase I to treat solid tumors. ALKS 3831 is a combination of samidorphan and olanzapine. ALKS 4230...
...regular trading session. The stock was off $3.33 to $37.50 in after-hours trade. Emily Cukier ALKS 4230, rdb 1419, rdb 1450 ALKS...
BioCentury | Mar 2, 2018
Clinical News

Nektar gains on updated response data for NKTR-214

...and natural killer cells in the tumor microenvironment. Alkermes plc (NASDAQ:ALKS), whose solid tumor candidate ALKS 4230...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...E6 and E7 antigens and an IL-2 adjuvant HPV-positive cancers Ph I/II Alkermes plc (NASDAQ:ALKS) ALKS 4230...
BioCentury | Feb 17, 2018
Financial News

Alkermes hits high following IL-2 deal

...A note from Jefferies analyst Biren Amin suggested that Alkermes and its solid tumor candidate ALKS 4230...
...earnings, Alkermes said it expects initial data this year from a Phase I trial of ALKS 4230...
...$275.4 million for the quarter, beating consensus estimates of $0.24 and $251 million, respectively. Elizabeth S. Eaton ALKS 4230 NKTR-214 Alkermes...
BioCentury | Jun 20, 2016
Clinical News

ALKS 4230: Phase I started

...Alkermes began a dose-escalation, dose-expansion Phase I trial to evaluate IV ALKS 4230 in patients who are...
...or intolerant to established therapies. Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 4230 (formerly RDB 1419 , RDB 1450...
BioCentury | Aug 19, 2013
Strategy

Delivering on NMEs

...abuse potential" compared with marketed analgesics, Pops said. ALKS 7106 is in toxicology studies. Alkermes' RDB 1419...
...selectivity and mode of action over the native protein molecule," Pops told BioCentury. "We think RDB 1419...
...recombinant form of interleukin-2 (IL-2) marketed by Novartis AG to treat melanoma and renal cancer. RDB 1419...
Items per page:
1 - 10 of 12